During tumor progression, variants may arise that grow more vigorously. The fate of such variants depends upon the balance between aggressiveness of the variant and the strength of the host immunity. Although enhancing host immunity to cancer is a logical objective, eliminating host factors necessary for aggressive growth of the variant should also be considered. The present study illustrates this concept in the model of a spontaneously occurring, progressively growing variant of an ultraviolet light-induced tumor. The variant produces chemotactic factors that attract host leukocytes and is stimulated in vitro by defined growth factors that can be produced or induced by leukocytes. This study also shows that CD8+ T-cell immunity reduces the rate of tumor growth; however, the variant continues to grow and kills the host. Treatment with a monoclonal anti-granulocyte antibody that counteracts the infiltration of the tumor cell inoculum by non-T-cell leukocytes did not interfere with the CD8+ T-cell-mediated immune response but resulted in rejection of the tumor challenge, indicating a synergy between CD8+ T-cell-mediated immunity and the inhibition of paracrine stimulation. 
upon transfer to normal mice do not regress but grow to kill the host. Several mechanisms of escape have been identifiedfor example, selective loss of the T-cell-recognized target antigen (2) or loss of the particular major histocompatibility complex class I molecule presenting the antigen (2, 3) . Interestingly, however, most progressor variants of UV-induced regressor tumors selected in immunocompetent hosts must use some other mechanism to escape because these variants retain the T-cell-recognized antigen and the presenting major histocompatibility complex class I molecule (2) . Recently, we have found evidence suggesting that the ability of such antigenpositive progressor variants to form tumors in normal hosts can correlate with acquisition of sensitivity to stimulation by paracrine growth factors (ref. 4 ; and L.P.S., unpublished work). Such factors were postulated to come from inflammatory stromal cells surrounding the cancer cells; the variants produced more chemotactic factors for inflammatory cells and were stimulated in vitro by growth factors produced by the inflammatory cells (4) . Furthermore, elimination of cells expressing the granulocyte marker Gr-1 slowed the growth of these tumors in T-cell-deficient mice (4) . We hypothesized that paracrine stimulation of growth might outstrip T-cellmediated inhibition of tumor growth. The purpose of the present study was to test this notion and, indeed, we found that
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. depletion of granulocytes allowed CD8+ immunity to eradicate the malignant cells, thus showing an important mechanism of tumor escape and suggesting additional approaches for treatment of some cancers.
MATERIALS AND METHODS
Mice and Tumors. Five-to ten-week-old C3H nude mice, normal BALB/c, and C3H/HeN mammary tumor virusnegative (MTV-) mice were purchased from the Frederick Cancer Research Facility. The 4102-RE, the 6132A-RE, and the 6134A-RE tumors were induced by UV light in C3H/HeN mice and adapted to culture as described (2, 5 Immunology (Fig. 3) . A previous study using rats and a different monoclonal antibody to deplete neutrophils found that such treatment inhibited delayed-type hypersensitivity to sheep erythrocytes and the primary and effector phases of transplantation resistance to syngeneic rat tumors (8) . We therefore determined whether the RB6-8C5 anti-Gr-1 antibody would affect the generation of CTL. In repeated experiments we failed to find any evidence that a single anti-Gr-1 antibody treatment reduced or increased CTL responses in popliteal lymph nodes of mice injected in foot pads with allogeneic cells. Also, spleen or lymph node cells of antibody-treated mice responded normally in mixed lymphocyte culture (data not shown). Finally, splenic lymphocytes, obtained from 4102-REtumor-immunized mice that had been treated with anti-Gr-1 antibody for 3 weeks, responded the same as lymphocytes from non-antibody-treated controls in generating 4102-specific CTL when restimulated in culture (Fig. 4) . Similar results were found in several repeated experiments.
It remained a possibility that multiple injections of granulocyte-depleting antibody could lead to an overproduction of granulocytes. These newly produced granulocytes could be resistant to further depletion and might actually become cytolytic. Chronic treatment with anti-Gr-1 visibly increased spleen size, and these spleens consistently contained 20-50% more nucleated cells than spleens from untreated mice. However, the number of mature granulocytes in the spleens of chronically treated mice was decreased from 6% to 0% of the nucleated cells compared with 4102-PRO tumor-immune untreated mice, whereas the number of immature "ring-form" granulocytes was doubled from 16% to 31%. Furthermore, mice treated repeatedly with the anti-Gr-1 antibody at 3-day intervals remained free of mature granulocytes in the peripheral blood, so that there were <1% mature granulocytes before each reinjection of the antibody.
Anti-Gr-1 Antibody Treatment Leads to Regression of the Progressor Variant. The above experiments indicated that 4102-PRO tumor was restrained but not eliminated by CD8+ The same antibody binds very effectively and specifically to a subset of murine bone marrow cells at low dilution (250 ng/ml) as described (6) . The isotype control antibody (7) shows no reactivity. Even at 25 ,ug/ml tumor cells do not react to the anti-Gr-1 antibody (data not shown). The second step antibody was a goat anti-rat IgG F(ab')2 fluorescein isothiocyanatelabeled antibody (Caltag, South San Francisco, CA). Ten thousand cells were analyzed by FACSCAN II using lysis II software (Becton Dickinson). C3H/HeN mice were immunized by injecting five 1-mm3 tumor fragments of 4102-RE tumor from a C3H nude mouse s.c. Spleens were aseptically removed 22 days after tumor challenge. Spleen cells were prepared and cultured as described. Six days later a cytolysis assay was done by using as targets the 4102-PRO tumor line (-) and the unrelated syngeneic UV-induced tumor cell line 6134A (-) as a control for specificity.
immunity and that anti-Gr-1 treatment had no measurable effect on the generation of tumor-specific CTL. We had reported (4) that this treatment slowed the growth of 4102-PRO tumor in nude mice; thus, antibody treatment might slow tumor growth in normal mice enough to allow the T-cellmediated immune response to become effective in eradicating the tumor challenge. C3H/HeN mice were treated every 3 days with 200 ,ul of anti-Gr-1 i.p. beginning on the day of tumor challenge and lasting until day 21 after tumor challenge. Table  1 shows that in three experiments the majority of normal mice treated with the anti-Gr-1 had rejected the tumors completely 1 mo after tumor challenge. Fig. 5 shows that those 4102-PRO tumors that grew in the anti-Gr-1-treated mice grew significantly slower than in untreated or isotype-control-treated mice (P < 0.0001). Not discernible in Fig. 5 are the four 4102-PRO tumors that were rejected by anti-Gr-1-treated mice. These tumors grew to 0.18 cm3 + 0.02 SEM on day 7 and were 0.06 cm3 + 0.01 SEM on day 10 before being completely rejected on day 21 . The three tumors that eventually grew were 0.15 cm3 + 0.03 SEM on day 7 and 0.06 cm3 + 0.03 SEM on day 10 and thus were similar in size as those rejected. Table 1 , which shows six nontreated mice, seven anti-Gr-1-treated mice, and four isotype control-treated mice.
DISCUSSION
We have demonstrated that the 4102-PRO tumor variant induces CTL in vivo as effectively as the parental 4102 cells. This tumor not only remained sensitive to lysis by specific T cells in vitro but could also induce a 4102-specific CTL response in vivo. 4102-PRO tumors grew considerably faster in the absence of CD8+ T cells (in nude or anti-CD8-treated mice) than in normal syngeneic mice, indicating that T cells were responding to the tumor. Apparently, the T cells were not prevented from being induced, being recruited to the tumor site, and slowing its growth.
In a naive mouse, it normally takes at least 10 days to induce a specific CTL response to a challenge with tumor cells. The optimal time for recovering specific CTL from spleens of such mice is 2-3 weeks; this is also the time it takes for a T-cellcompetent mouse to completely reject a regressor tumor, which forms a small but detectable tumor during the first 2 weeks. However, even at the peak of growth before regressing, the 4102-RE tumor is consistently smaller than the progressor variant. Furthermore, we had previously reported that 4102-PRO tumor grows significantly faster than 4102-RE tumor in nude mice, and we found evidence suggesting that this difference was due to 4102-PRO tumor having acquired sensitivity to paracrine stimulation by several growth factors (4). In particular, we found that the growth of the 4102-PRO tumor variant, but not of the parental 4102-RE tumor cells, was stimulated by recombinant transforming growth factor (, epidermal growth factor, platelet-derived growth factor, and basic fibroblast growth factor, factors either produced directly by granulocytes or produced by other infiltrative cells that are attracted and stimulated by factors released from granulocytes. At present it is not clear which factor and cell types are the ultimate paracrine stimulators. Depletion of the Gr-1+ cells with a monoclonal antibody in vivo led to a significantly slower growth of 4102-PRO tumor in nude mice, although this treatment never led to tumor rejection by these mice (4) . Such mice were not only severely depleted of granulocytes but also failed to recruit other inflammatory cells to the site of tumor injection (L.P.S., unpublished work) in agreement with previous studies of others (9, 10) . Anti-natural killer antibodies and the isotype control antibody anti-CD4 did not reduce the 4102-PRO tumor growth in the nude mice (4) and the antiGr-1 antibody did not bind to the tumor cells. In the present study, we found that treatment of normal mice with anti-Gr-1 led not only to a significant decrease in 4102-PRO tumor growth but to complete rejection of the tumors in the majority of mice. (The fact that one of four mice in both the non-treated and isotype control-treated groups rejected the tumor in experiment 2 may be due to the smaller tumor challenge given.)
We do not know how commonly the growth of primary cancers is restrained in humans by T-cell (14) , even though prior removal of the cancer may be necessary for the immunity to become detectable. Continuous tumor growth can eclipse antitumor immunity (15, 16) . Counteracting paracrine stimulation might reverse tumor-induced immune suppression and unmask existing tumor immunity. In fact, the same growth factors-e.g., transforming growth factor ( might act as paracrine stimulators (17) , as well as negative regulators of CD8+ T-cell immunity (18) .
Considerable work in a rat model has provided evidence that depletion of neutrophils with a monoclonal antibody can interfere with immune responses (8, 9, 19) . Both priming and elicitation of delayed-type hypersensitivity to sheep erythrocytes were inhibited; recruitment of mononuclear leukocytes and CD4+ T cells, but not CD8+ T cells, into the site of delayed-type hypersensitivity was also inhibited in rats depleted of neutrophils. Nevertheless, the investigators found that depletion of neutrophils abrogated the induction of CD8+ T cells that would otherwise have inhibited the growth of tumor cells (19) . By contrast, the induction of CD8+ responses to the tumor used here does not appear to be altered. The reasons for this discrepancy are not clear. The two antibodies might react to different types of target molecules. Furthermore, differences in the requirement for CD4+ T cells for the induction of a CD8+ T-cell response, could be a reason. CD8+ T cells required for rejection of the particular rat tumor were induced in the presence of CD4+ T cells, which alone were not effective in decreasing tumor growth. We have shown in our tumor model that CD8+ but not CD4+ cells are required for the rejection of the 4102-RE tumor used here and seven other UV-induced tumors tested (2).
Although we do not know how commonly the growth of human cancers depends on an environment that is influenced by Gr-1 + cells, it is likely that many tumors evolve during tumor progression to a stage where they can use growth factors provided by the host in the local environment (20) . We do not know the molecular basis of the heritable change that generated the 4102-PRO tumor variant, but the increased sensitivity to several growth factors and decreased serum dependence is consistent with a heritable change affecting the general growth responsiveness. A more precise understanding of the molecular events leading to paracrine stimulation will be helpful in designing more specific and powerful inhibitors. Also, we do not know which tumor types, sites, and stages of growth could be affected by interfering with paracrine stimulation, but complete rejection of the cancer cells clearly requires that tumors be antigenic and be recognized by CD8+ T cells. In our model, a CTL response to the tumor is generated by the growing tumor but by itself cannot overcome the rapid growth of the tumor. In other cases, the synergistic antitumor response may first need to be induced or upregulated-e.g., by immunizing with tumor cells transfected with genes encoding cytokines (21) (22) (23) (24) (25) , costimulatory molecules (26, 27) , antisense growth factors (28) , or antisense growth factor receptors (29) before tumor rejection is achieved.
Granulocytopenia occurring alone or as a component of more severe pancytopenia is a common complication of many kinds of cancer therapy. The beneficial effects of anticancer agents that suppress myelopoiesis are thought to result from direct cytotoxicity on cancer cells, and the complications are prevented or treated with antibiotics and/or replacement therapy. Our present findings introduce the surprising concept that the complication of granulocytopenia occurring with present therapies may contribute or account for some favorable outcomes.
Producing granulocytopenia by depleting granulocytes with antibody does not affect other bone-marrow-derived cell types or B and T cells, and recovery is reversible and rapid within a few days after treatment is discontinued. Nevertheless, such antibody-induced granulocytopenia required simultaneous treatment of the host with antibiotics to reduce the risk of severe microbial infections. Therefore, it would be advantageous to identify the precise molecules and cell types directly involved in the paracrine stimulation in vivo so that more selective inhibitors, which have fewer or less severe potential side effects, may be developed. In any case, the results of this study support the concept that counteracting paracrine stimulation to complement the effects of existing or induced antitumor immunity may prove effective in treating some cancers.
